Modulation of liver X receptor signaling as a prevention and therapy for colon cancer

Medical Hypotheses

Volumn 76, Issue 5, 2011, Pages 697-699

  Chuu, Chih Pin ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

22 HYDROXYCHOLESTEROL; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APC PROTEIN; ATI 829; BETA CATENIN; CAMPESTEROL; CYCLIN A2; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PHYTOSTEROL; PROTEIN P53; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SITOSTEROL; STIGMASTEROL; UNCLASSIFIED DRUG; WNT PROTEIN; YT 32;

ARTICLE; CANCER INHIBITION; COLON CANCER; DIETARY INTAKE; DRUG EFFECT; DRUG MECHANISM; HUMAN; NONHUMAN; PROSTATE CANCER; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, NUDE; MODELS, THEORETICAL; NEOPLASM TRANSPLANTATION; ORPHAN NUCLEAR RECEPTORS; PHOSPHORYLATION; PHYTOSTEROLS; SIGNAL TRANSDUCTION; WNT PROTEINS;

MAMMALIA; MURINAE; MUS MUSCULUS;

EID: 79954440969     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.037     Document Type: Article

References (36)

1. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361(25):2449-2460.
2. Goss K.H., Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000, 18(9):1967-1979.
3. Uno S., Endo K., Jeong Y., et al. Suppression of beta-catenin signaling by liver X receptor ligands. Biochem Pharmacol 2009, 77(2):186-195.
4. Chuu C.P., Kokontis J.M., Hiipakka R.A., Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 2007, 14(5):543-553.
5. Seol W., Choi H.S., Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995, 9(1):72-85.
6. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116(3):607-614.
7. Edwards P.A., Kennedy M.A., Mak P.A. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vasc Pharmacol 2002, 38(4):249-256.
8. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci USA 1994, 91(23):10809-10813.
9. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995, 9(9):1033-1045.
10. Teboul M., Enmark E., Li Q., Wikström A.C., Pelto-Huikko M., Gustafsson J.A. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci USA 1995, 92(6):2096-2100.
11. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383(6602):728-731.
12. Forman B.M., Ruan B., Chen J., Schroepfer G.J., Evans R.M. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997, 94(20):10588-10593.
13. Schultz J.R., Tu H., Luk A., et al. Role of LXRs in control of lipogenesis. Genes Dev 2000, 14(22):2831-2838.
14. Collins J.L., Fivush A.M., Watson M.A., et al. Identification of a nonsteroidal liver x receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 2002, 45(10):1963-1966.
15. Peng D., Hiipakka R.A., Dai Q., et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 2008, 327(2):332-342.
16. Song C., Liao S. Hypolipidemic effects of selective liver X receptor alpha agonists. Steroids 2001, 66(9):673-681.
17. Kaneko E., Matsuda M., Yamada Y., Tachibana Y., Shimomura I., Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 2003, 278(38):36091-36098.
18. Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.P., Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 2004, 64(21):7686-7689.
19. Chuu C.P., Hiipakka R.A., Kokontis J.M., Fukuchi J., Chen R., Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 2006, 66(13):6482-6486.
20. Vigushin D.M., Dong Y., Inman L., et al. The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer. Med Oncol 2004, 21(2):123-131.
21. Scoles D.R., Xu X., Wang H., et al. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol 2010, 116(1):109-116.
22. Geyeregger R., Shehata M., Zeyda M., et al. Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. J Leukocyte Biol 2009, 86(5):1039-1048.
23. Vedin L., Lewandowski S.A., Parini P., Gustafsson J., Steffensen K.R. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30(4):575-579.
24. De Gottardi A., Touri F., Maurer C.A., et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004, 49(6):982-989.
25. Plat J., Nichols J.A., Mensink R.P. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J Lipid Res 2005, 46(11):2468-2476.
26. De Stefani E., Boffetta P., Ronco A.L., et al. Plant sterols and risk of stomach cancer: a case-control study in Uruguay. Nutr Cancer 2000, 37(2):140-144.
27. Ronco A., De Stefani E., Boffetta P., Deneo-Pellegrini H., Mendilaharsu M., Leborgne F. Vegetables, fruits, and related nutrients and risk of breast cancer: a case-control study in Uruguay. Nutr Cancer 1999, 35(2):111-119.
28. Mendilaharsu M., De Stefani E., Deneo-Pellegrini H., Carzoglio J., Ronco A. Phytosterols and risk of lung cancer: a case-control study in Uruguay. Lung Cancer 1998, 21(1):37-45.
29. McCann S.E., Ambrosone C.B., Moysich K.B., et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005, 53(1):33-41.
30. Awad A.B., Chen Y.C., Fink C.S., Hennessey T. Beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. Anticancer Res 1996, 16(5A):2797-2804.
31. Jayaprakasha G.K., Jadegoud Y., Nagana Gowda G.A., Patil B.S. Bioactive compounds from sour orange inhibit colon cancer cell proliferation and induce cell cycle arrest. J Agric Food Chem 2010, 58(1):180-186.
32. Jayaprakasha G.K., Mandadi K.K., Poulose S.M., Jadegoud Y., Nagana Gowda G.A., Patil B.S. Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from Poncirus trifoliata (L). Raf Bioorg Med Chem 2007, 15(14):4923-4932.
33. Awad A.B., Gan Y., Fink C.S. Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer 2000, 36(1):74-78.
34. Awad A.B., Fink C.S., Williams H., Kim U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 2001, 10(6):507-513.
35. Awad A.B., Downie A., Fink C.S., Kim U. Dietary phytosterol inhibits the growth and metastasis of MDA-MB-231 human breast cancer cells grown in SCID mice. Anticancer Res 2000, 20(2A):821-824.
36. Spector D., Anthony M., Alexander D., Arab L. Soy consumption and colorectal cancer. Nutr Cancer 2003, 47(1):1-12.